Trial
NCT02811809
Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
Janssen Scientific Affairs, LLC
Condition
Prostate Cancer
Intervention
Apalutamide
Why stopped
Withdrawn due to operational issues. The study was withdrawn early, before enrolling its first participant.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-02-27